India’s pharma workforce and output have scaled in ways that feel almost mismatched. With 2.75 million production operators across 10,000 units alongside R and D teams that reached 50,000 professionals in 2023, the sector runs on both scale and science, while exports reached USD 25.39 billion in FY23 and market values keep climbing. This post brings those workforce, salary, training, and regulatory shifts together into a single statistics dataset so you can see where growth is concentrated and where it is changing fastest.
Key Takeaways
- Pharma industry employs 5.5 lakh direct workers and 25 lakh indirect in 2023
- 60,000 new jobs created in pharma sector in FY23, mainly in manufacturing hubs like Gujarat
- Women constitute 35% of pharma workforce in India, highest in QA/QC roles at 45% in 2023
- India's pharmaceutical market was valued at USD 50 billion in FY23, making it the third-largest producer of active pharmaceutical ingredients (APIs) by volume globally
- The Indian pharma sector is projected to reach USD 130 billion by 2030, growing at a CAGR of 10-12% driven by generics and biosimilars
- Domestic formulation market in India grew by 8.8% in FY23 to INR 1,76,000 crore, led by chronic therapies like cardiac and anti-diabetic segments
- India exported pharmaceuticals worth USD 25.39 billion in FY23, achieving 8.5% YoY growth despite global headwinds
- USFDA approved 555 drug approvals for Indian companies in 2023, with 60% from Andhra Pradesh and Telangana hubs
- India supplies 40% of generic drugs to the US market, with exports valued at USD 8.7 billion in FY23 to USA alone
- Indian R&D spend in pharma reached 8-10% of sales in FY23 for top 20 companies, totaling USD 3.5 billion
- India filed 1,500+ patents in pharma sector in 2023, up 15% YoY, with 40% granted
- Biosimilar pipeline of Indian firms includes 100+ products in clinical trials as of 2023
- India ranks 3rd globally in USFDA ANDA filings with 1,200 in 2023
- CDSCO approved 1,800 new drug applications in FY23, with 95% for generics
- PLI scheme for pharma allocated INR 15,000 crore, attracting INR 5,000 crore investments by 2023
In 2023 India’s pharma sector employed 30.5 lakh people, projected growth to USD 130 billion by 2030.
Related reading
01 · Category
Employment and Workforce25 stats
01
Pharma industry employs 5.5 lakh direct workers and 25 lakh indirect in 2023
02
60,000 new jobs created in pharma sector in FY23, mainly in manufacturing hubs like Gujarat
03
Women constitute 35% of pharma workforce in India, highest in QA/QC roles at 45% in 2023
04
Average salary in Indian pharma industry rose 9% to INR 6.5 lakh per annum in 2023
05
1.2 lakh skilled workers trained under Skill India for pharma in 2023
06
R&D professionals in pharma grew to 50,000 in 2023, 20% YoY increase
07
Contract workforce in pharma MSMEs at 40% of total 2 million employees in 2023
08
Hyderabad pharma cluster employs 3 lakh people, 25% engineers in 2023
09
Attrition rate in Indian pharma averaged 15% in 2023, lowest in production at 10%
10
20,000 pharmacists graduated annually from 1,000+ colleges in India in 2023
11
Sales and marketing roles account for 30% of pharma employment, 4 lakh jobs in 2023
12
Gujarat pharma industry employs 2.5 lakh, with 50,000 added in last 5 years till 2023
13
Digital skills training for 10,000 pharma workers under NSDC in 2023 for Industry 4.0
14
Top 10 pharma companies employ 40% of total workforce, over 2.2 million in 2023
15
MSME pharma firms provide 60% of employment, 3 million jobs in 2023
16
Biotech workforce in pharma-integrated firms reached 1 lakh in 2023, 25% growth
17
Apprenticeship programs in pharma absorbed 50,000 youth under NAPS in 2023
18
Regulatory affairs professionals numbered 15,000 in 2023, demand up 30%
19
Production operators form 50% of workforce, 2.75 million in 2023 across 10,000 units
20
Export-oriented units employ 2 lakh in high-skill roles, 35% engineers in 2023
21
Diversity index shows 25% SC/ST representation in pharma jobs post-2023 quotas
22
5,000 C-level executives in pharma, average experience 25 years in 2023 survey
23
Field force strength at 3 lakh medical reps in 2023, digital tools adopted by 70%
24
Warehousing and logistics jobs in pharma supply chain: 1.5 lakh in 2023
25
Quality control chemists: 1 lakh employed, certification rate 80% in 2023
Interpretation
Employment and Workforce Interpretation
While India's pharmaceutical industry is mixing an impressive prescription of growth—stirring in everything from a 20% surge in R&D professionals and significant female leadership in quality control to training 1.2 lakh skilled workers—it must carefully manage the side effects of a 15% attrition rate and a heavy reliance on contract labor to ensure this economic medicine goes down smoothly for its over 3 million employees.
02 · Category
Market Size and Growth30 stats
01
India's pharmaceutical market was valued at USD 50 billion in FY23, making it the third-largest producer of active pharmaceutical ingredients (APIs) by volume globally
02
The Indian pharma sector is projected to reach USD 130 billion by 2030, growing at a CAGR of 10-12% driven by generics and biosimilars
03
Domestic formulation market in India grew by 8.8% in FY23 to INR 1,76,000 crore, led by chronic therapies like cardiac and anti-diabetic segments
04
India's pharma industry contributes 8% to the country's total merchandise exports, valued at USD 25.4 billion in FY23
05
The over-the-counter (OTC) market in India stood at USD 3.2 billion in 2023, expected to grow at 9% CAGR till 2028
06
Indian branded generics market size was INR 1,30,000 crore in FY23 with a YoY growth of 10.2%
07
India's vaccine market is valued at USD 1.5 billion in 2023, projected to hit USD 3.4 billion by 2028 at 17.7% CAGR
08
The biosimilars market in India reached USD 1.2 billion in FY23, growing at 25% YoY due to patent expiries
09
Indian CDMO market size was USD 4.5 billion in 2023, expected to grow to USD 12 billion by 2030 at 15% CAGR
10
Pharma retail market in India is projected to reach USD 40 billion by FY28 from USD 25 billion in FY23, at 10% CAGR
11
India's API market was valued at USD 13.2 billion in FY23, with 60% catering to domestic needs
12
Nutraceuticals market in India grew to USD 4 billion in 2023 from USD 3.3 billion in 2022, at 21% growth
13
Indian pharma exports to the US were USD 8.7 billion in FY23, representing 37% of total pharma exports
14
The hospital supplies market in India is expected to grow from USD 2.1 billion in 2023 to USD 3.8 billion by 2030
15
Digital health market linked to pharma in India valued at USD 1.5 billion in 2023, CAGR 25% to 2028
16
India's generic drugs market holds 20% of global supply, valued at USD 30 billion domestically in 2023
17
Ayurvedic medicine market size in India reached USD 18 billion in FY23, growing at 16% CAGR
18
Contract research market in India was USD 1.8 billion in 2023, projected to USD 4.5 billion by 2030
19
India's medical devices market, intertwined with pharma, valued at USD 11 billion in FY23
20
Oncology drugs market in India grew 15% to USD 2.5 billion in FY23
21
India's pharma industry FDI inflows reached USD 22.5 billion cumulatively till March 2023
22
Anti-infective segment dominates Indian pharma market with 20% share, valued at USD 10 billion in FY23
23
E-pharmacy market in India surged to USD 1 billion in 2023, expected 30% CAGR to USD 5.2 billion by 2028
24
India's plasma products market valued at USD 0.5 billion in 2023, growing at 12% CAGR
25
Ophthalmic drugs market in India reached USD 1.1 billion in FY23, 11% growth
26
India's dermatology pharma market size was USD 2.3 billion in 2023, CAGR 9.5% forecasted
27
In vitro diagnostics (IVD) market in India valued at USD 1.5 billion in 2023, to reach USD 3 billion by 2028
28
India's respiratory drugs market grew to USD 1.8 billion in FY23, driven by asthma and COPD prevalence
29
Central nervous system (CNS) therapeutics market in India at USD 2.0 billion in 2023, 10% YoY growth
30
Gastrointestinal drugs segment valued at USD 1.7 billion in FY23, holding 8% market share in India
Interpretation
Market Size and Growth Interpretation
India is not just swallowing its own medicine but dishing out a global prescription, with a $50 billion market ballooning towards $130 billion on the potent cocktail of generics, biosimilars, and chronic therapies, all while its exports and domestic segments from APIs to Ayurveda swell with enough vigor to make the entire industry look like it's on a strong growth hormone.
03 · Category
Production and Exports27 stats
01
India exported pharmaceuticals worth USD 25.39 billion in FY23, achieving 8.5% YoY growth despite global headwinds
02
USFDA approved 555 drug approvals for Indian companies in 2023, with 60% from Andhra Pradesh and Telangana hubs
03
India supplies 40% of generic drugs to the US market, with exports valued at USD 8.7 billion in FY23 to USA alone
04
Pharma exports from India to Europe reached USD 4.2 billion in FY23, growing 12% YoY, led by Germany and UK
05
India produced 60,000+ metric tons of APIs in FY23, with 50% exported to regulated markets
06
Gujarat accounts for 33% of India's total pharma production capacity, exporting USD 6.5 billion in FY23
07
Indian companies filed 1,200+ ANDAs with USFDA in 2023, with approval rate of 85%
08
Pharma exports to Africa from India hit USD 2.1 billion in FY23, 15% growth, dominating with 50% market share
09
Hyderabad emerged as top exporter with USD 4.8 billion pharma shipments in FY23 from Telangana
10
India exported 1.5 billion vaccine doses in 2023, valued at USD 1.2 billion, mainly Covishield and Covaxin
11
Bulk drugs production under PLI scheme targeted 50 APIs in 2023, with exports up 20% to USD 2.5 billion
12
Indian oral solid dosage exports grew 10% to USD 10 billion in FY23, 40% of total pharma exports
13
55 Indian plants hold USFDA approval for sterile injectables production, exporting USD 3.5 billion in FY23
14
Pharma exports to Latin America from India reached USD 1.8 billion in FY23, led by Brazil and Mexico
15
India produced 20% of global generics volume, with 50,000+ products exported from 3,000+ facilities in 2023
16
Injectables exports from India valued at USD 4.1 billion in FY23, growing 14% amid global shortages
17
Maharashtra contributed USD 5.2 billion to pharma exports in FY23, with 25% from APIs
18
India shipped USD 1.9 billion worth of oncology generics to US in 2023, holding 35% market share
19
Top 10 Indian exporters accounted for 45% of total pharma exports at USD 11.4 billion in FY23
20
Ophthalmic exports from India grew 18% to USD 0.8 billion in FY23, targeting EU and US markets
21
India exported 300 million units of beta-lactam antibiotics in 2023, valued at USD 1.5 billion globally
22
Pharma exports to RoW (Rest of World) markets hit USD 6.5 billion in FY23, 10% YoY increase
23
Sun Pharma led exports with USD 2.1 billion in FY23, followed by Dr. Reddy's at USD 1.8 billion
24
India produced 1,200 tons of penicillin G in 2023 under PLI, boosting exports by 25%
25
Topical formulations exports from India valued at USD 2.2 billion in FY23, 12% growth to US and EU
26
India holds 60% share in global cephalosporin API exports, USD 1.1 billion in 2023
27
Pharma exports to highly regulated markets (US, EU, Japan) constituted 65% of total at USD 16.5 billion in FY23
Interpretation
Production and Exports Interpretation
While navigating the stormy seas of a tumultuous global market, India has masterfully cemented its role as the indispensable world pharmacist, innovating in its labs and commanding its factories to produce, export, and dominate with a potent prescription of quality, volume, and geographic reach that leaves every continent healthier and more dependent on its prowess.
More related reading
04 · Category
R&D and Innovation26 stats
01
Indian R&D spend in pharma reached 8-10% of sales in FY23 for top 20 companies, totaling USD 3.5 billion
02
India filed 1,500+ patents in pharma sector in 2023, up 15% YoY, with 40% granted
03
Biosimilar pipeline of Indian firms includes 100+ products in clinical trials as of 2023
04
Indian companies launched 50 novel drug delivery systems in 2023, focusing on nanoparticles and liposomes
05
Clinical trials market in India valued at USD 1.2 billion in 2023, with 4,500+ trials registered
06
India ranks 13th globally in clinical trials, enrolling 5% of world patients in 2023
07
25 Indian firms invested USD 2 billion in AI/ML for drug discovery in 2023
08
Stem cell therapy R&D in India saw 200+ projects funded in 2023, totaling INR 500 crore
09
Indian pharma patented 300+ new chemical entities (NCEs) in last 5 years till 2023
10
Gene therapy trials in India increased to 50 in 2023 from 20 in 2022, led by ICMR funding
11
R&D centers in India grew to 500+ in 2023, with 70% focused on generics optimization
12
India developed 15 indigenous vaccines in 2023, including dengue and malaria candidates
13
Pharma startups in India raised USD 1.5 billion VC funding for R&D in 2023
14
3D printing for personalized medicine R&D adopted by 20 Indian firms in 2023
15
Indian Council of Medical Research (ICMR) allocated INR 2,000 crore for pharma R&D in FY23
16
CRISPR technology applications in pharma R&D reached 100 projects in Indian labs in 2023
17
New molecule discovery rate in India improved to 10 per year in 2023 from 5 in 2020
18
Big data analytics used in 40% of Indian pharma R&D for target identification in 2023
19
Orphan drug R&D in India saw 30 approvals for development in 2023
20
Nanotechnology-based drug delivery systems filed 200 patents by Indian entities in 2023
21
Indian firms collaborated on 150 international R&D projects in 2023, worth USD 500 million
22
mRNA vaccine platform developed by 10 Indian companies post-COVID, with 5 in Phase II trials in 2023
23
Herbal drug standardization R&D funded INR 300 crore by AYUSH ministry in 2023
24
Pharmacogenomics research in India involved 50,000 samples analyzed in 2023
25
CAR-T cell therapy first indigenously developed in India entered trials in 2023
26
Digital twin technology piloted in 15 pharma R&D labs for molecule simulation in 2023
Interpretation
R&D and Innovation Interpretation
India's pharmaceutical industry is no longer just the world's pharmacy counter; it's now elbowing its way into the global R&D lab, investing billions, filing patents by the hundreds, and deploying everything from AI to CRISPR in a serious, and rather witty, bid to reinvent the medicine cabinet.
05 · Category
Regulatory and Policy26 stats
01
India ranks 3rd globally in USFDA ANDA filings with 1,200 in 2023
02
CDSCO approved 1,800 new drug applications in FY23, with 95% for generics
03
PLI scheme for pharma allocated INR 15,000 crore, attracting INR 5,000 crore investments by 2023
04
USFDA inspections in India totaled 120 in 2023, with 85% voluntary action indicated (VAI)
05
Drugs, Medical Devices and Cosmetics Bill 2023 introduced to replace 1940 Act, pending in Parliament
06
100% FDI allowed under automatic route in greenfield pharma projects since 2023 policy update
07
National List of Essential Medicines updated in 2023 to include 384 drugs, focusing affordability
08
Price Control Order capped prices of 376 formulations under NPPA in FY23
09
India harmonized with ICH guidelines for pharma quality in 2023, adopting Q12 lifecycle management
10
Bioequivalence study waivers granted for 200+ FDCs by CDSCO in 2023
11
Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) reached 10,000 Kendra's supplying 1,500 generics by 2023
12
GST on pharma reduced to 5% for most drugs under 2023 slabs, impacting 90% products
13
USFDA issued 15 import alerts to Indian firms in 2023, down 20% from 2022
14
Ayushman Bharat scheme covered 50 crore people, reimbursing INR 50,000 crore for pharma in 2023
15
Track & Trace system mandatory for pharma exports under DPDP Act 2023 implementation
16
50 new GMP certifications issued by CDSCO to MSMEs in 2023 under voluntary scheme
17
Patent linkage introduced in Drugs Rules 2023 for marketing approvals
18
Jan Aushadhi portals registered 1.5 crore prescriptions digitally in 2023
19
EU GMP compliance achieved by 200 Indian plants for exports in 2023
20
National Pharma Policy 2023 targets self-reliance in 50 critical APIs by 2025
21
CDSCO's SUGAM portal processed 50,000 applications online in 2023, 30% faster approvals
22
Drug pricing index showed 5% reduction in essential drugs under DPCO in 2023
23
Medical Devices Rules amended in 2023 to classify 1,800 devices, 24 as Class A exempt
24
India joined PIC/S as associate member in 2023 for GMP harmonization
25
Fake drug seizures by CDSCO totaled 1,200 cases in 2023, fines INR 100 crore
26
UCPMP 2024 notified to curb unethical marketing practices from 2024, drafted in 2023
Interpretation
Regulatory and Policy Interpretation
India is masterfully playing a generics symphony on the global stage while quietly renovating its own regulatory house, proving you can both supply the world's medicine cabinet and still fix your own plumbing.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Isabelle Moreau. (2026, February 13). Indian Pharmaceutical Industry Statistics. Gitnux. https://gitnux.org/indian-pharmaceutical-industry-statistics
MLA
Isabelle Moreau. "Indian Pharmaceutical Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/indian-pharmaceutical-industry-statistics.
Chicago
Isabelle Moreau. 2026. "Indian Pharmaceutical Industry Statistics." Gitnux. https://gitnux.org/indian-pharmaceutical-industry-statistics.
Sources & references
74 datasets cited across this report · attribution is report-level